Name | ABP 215 |
---|
Description | ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab (HY-P9906)) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA (VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research[1][2]. |
---|---|
Related Catalog | |
In Vitro | ABP 215 (Bevacizumab-awwb) 与 VEGF-A 结合,阻止 VEGF-A 与内皮细胞表面的 VEGF 受体结合,抑制内皮细胞增殖和新血管形成,从而导致肿瘤脉管系统正常化。 |
References |
No Any Chemical & Physical Properties |